Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

PRINTO (the Paediatric Rheumatology International Trials Organisation)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2006 by Institute of Child Health.
Recruitment status was  Recruiting
Information provided by:
Institute of Child Health Identifier:
First received: December 22, 2006
Last updated: December 23, 2006
Last verified: December 2006
A comparison of outcome in children with JIA who are in remission on MTX, when MTX is then stopped for either 6 or 12 months

Condition Intervention
Juvenile Idiopathic Arthritis
Drug: methotrexate

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Institute of Child Health:

Estimated Study Completion Date: December 2006

Ages Eligible for Study:   up to 16 Years   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Any child with JIA who has gone into remission using methotrexate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00415935

Contact: Lucy Wedderburn, Dr

United Kingdom
Rheumatology ICH Recruiting
London, United Kingdom, WC1N 1EH
Contact: Lucy Wedderburn, Dr   
Sponsors and Collaborators
Institute of Child Health
Principal Investigator: Lucy Wedderburn, Dr Institute Of Child Health and Great Ormond Street Hospital
  More Information Identifier: NCT00415935     History of Changes
Other Study ID Numbers: 04RU01 
Study First Received: December 22, 2006
Last Updated: December 23, 2006
Health Authority: United Kingdom: Research Ethics Committee

Additional relevant MeSH terms:
Arthritis, Juvenile
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors processed this record on October 26, 2016